Advances in intravesical therapy of urinary bladder cancer

References

• Malmström PU, Busch C, Norlen BJ. Recurrence, progression, and survival in bladder cancer: a retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand. J Urol. NephroL 21,185–195 (1987).
   Google Scholar
• Hinotsu S, Akaza H, Ohashi Y, Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function. Cancer 86(9), 1818–1826 (1999).
   PubMedGoogle Scholar
• •Important paper regarding the timing of recurrence risk.
   Google Scholar
• Klan R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage Ti transitional cell carcinoma of the bladder. UroL 146,316–318 (1991).
   Google Scholar
• Oosterlinck W, Kurth KH, Schroder F et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single Ta, Ti papillary carcinoma of the bladder. J UroL 149,749–752 (1993).
   PubMed Web of Science ®Google Scholar
• •High-level evidence for the use of perioperative instillation.
   Google Scholar
• Page BH, Levison VB, Curwen MP. The site of recurrence of noninfiltrating bladder tumors. Br. UroL 50,237–242 (1978).
   Google Scholar
• Brausi M, Collette L, Kurth K et al. for the EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in Stage Ta Ti transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol. 41(5), 523-531(2002).
   Google Scholar
• ••The relation between surgery quality andrecurrence rate is analyzed.
   Google Scholar
• Cookson MS, Sarosdy ME Management of stage Ti superficial bladder cancer with intravesical bacillus Calmette—Guerin therapy.j UroL 148,797–801 (1992).
   PubMed Web of Science ®Google Scholar
• Freeman JA, Esrig D, Stein JP et al. Radical Cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 76,833–839 (1995).
   PubMed Web of Science ®Google Scholar
• Wolf H, Melsen F, Pederson SE, Nielson KT. Natural history of carcinoma in situ of the urinary bladder. Scan. J Urol. NephroL 157,147–151 (1994).
   Google Scholar
• Lamm DL. Long-term results of intravesical therapy for superficial bladder cancer. UroL Clin. North A177. 19,573–580 (1992).
   Google Scholar
• Dalton 5, Wientjes MG, Badalament RA et al. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res. 51,5144-5152 (1991).
   Google Scholar
• Wientjes MG, Badalament RA, Au JL. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother. PharmacoL 32,255–262 (1993).
   Google Scholar
• Au JL, Badalament RA, Wientjes MG et aL Methods to improve efficacy of intravesical mitomycin C: results of a randomized Phase III trial. J Nat] Cancer Inst. 93,597–604 (2001).
   PubMed Web of Science ®Google Scholar
• ••Proves the value of optimizingchemotherapy.
   Google Scholar
• Parmar MK, Freedman LS, Hargreave TB, Tolly DA. Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J UroL 142, 284–288 (1989).
   PubMed Web of Science ®Google Scholar
• •Important analysis of risk grouping.
   Google Scholar
• Bird VG, Soloway MS, Malmström PU. Intravesical chemotherapy in the treatment of superficial bladder cancer. In: Bladder Cancer: Current Diagnosis and Treatment. Droller MJ (Ed.), Humana Press, NJ, USA,183–224 (2000).
   Google Scholar
• Patterson AL, Greenberg RE, Weems L et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology56, 232–235 (2000).
   PubMed Web of Science ®Google Scholar
• Newling DW, Hetherington J, Sundaram SK, Robinson MR, Kisbenedek L. The use of valrubicin for the chemoresection of superficial bladder cancer — a marker lesion study. Eur. Urol. 39(6), 643–647 (2001).
   Google Scholar
• Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet353, 1689–1694 (1999).
   Google Scholar
• Akaza H, Koiso K, Ozono S et al. PMCJ-9 Study Group in Japan. A clinical study of PMCJ-9 (bacillus Calmette—Guerin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder. Jpn. Clin. Oncol. 33(8), 382–390 (2003).
   Google Scholar
• Yalcinkaya F, Kamis L, Ozteke O, Gunlusoy B, Yigitbasi O, Unal S. Prospective randomized comparison of intravesikal BCG therapy with standard dose versus low doses in superficial bladder cancer. Int. Urol. Nephrol. 30,41–44 (1998).
   PubMedGoogle Scholar
• Belldegrun AS, Franklin JR, O'Donnell MA et al. Superficial bladder cancer: the role of interferon-a. j Urol. 159,1793–1801 (1998).
   PubMed Web of Science ®Google Scholar
• Lamm DL, Dehaven JI, Riggs DR. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies. Eur.37\(Suppl. 3), 41–44 (2000).
   Google Scholar
• Bono AV, Hall RR, Denis L, Lovisolo JA, Sylvester R. Chemoresection in Ta—Ti bladder cancer. Members of the EORTC Genito-Urinary Group. Eur. Uml. 29, 385–390 (1996).
   Google Scholar
• Ali-el-dein B, el-Baz M, My AN et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J 158(1), 68–73 (1997).
   Google Scholar
• Malmström PU. A randomized comparative dose ranging study of interferon-a and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. BE jhat.89,1–11 (2002).
   Google Scholar
• Heney NM, Koontz WW, Weinstein R, Barton B. BCG in superficial bladder cancer. J Lira 135 (Suppl.), 184a (1986).
   Google Scholar
• Khanna OE Son DL, Son K et al. Multicenter study of superficial bladder cancer treated with intravesical bacillus Calmette—Guerin or adriamycin. Results of long-term follow-up. Urology38(3), 271–279 (1991).
   PubMedGoogle Scholar
• Akaza H, Hinotsu S, Aso Y, Kakizoe T, Koiso K. Bacillus Calmette—Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results. The Bladder Cancer BCG Study Group. Cancer 75(2), 552–559 (1995).
   Google Scholar
• Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Co-operative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. 1 Lira 156,1934-1940 (1996).
   Google Scholar
• ••First large combined anlysis of the efficacyof intravesical therapy.
   Google Scholar
• Bouffioux C, Denis L, Oosterlinck W et al. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European Organisation for Research on Treatment of Cancer randomized trial comparing intravesical instillations of thiotepa, doxorubicin, and cisplatin. j Urol. 148,297–301 (1992).
   PubMed Web of Science ®Google Scholar
• Kurth K, Tunn U, Ay R et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Lira 158(2), 378–384 (1997).
   Google Scholar
• Huland H, Kloppel G, Feddersen I et al. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Lira 144, 68–71 (1990).
   Google Scholar
• Buffioux C, Kurth KH, Bono A et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of two European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol. 153,934–941 (1995).
   Google Scholar
• Tolley DA, Parmar MK, Grigor KM et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow-up." Uml. 155,1233-1238 (1996).
   Google Scholar
• Ali-el-Dein B, Nabeeh A, el-Baz M, Shamaa S, Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence aftertransurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br. Lira 79,731–735 (1997).
   Google Scholar
• Flamm J. Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer. Eur. Uml. 17,119–124 (1990).
   PubMedGoogle Scholar
• Okamura K, Kinukawa T, Tsumura Y et al. A randomized study of short- versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur. Lira 33,285–288 (1998).
   Google Scholar
• Sylvester RJ, Oosterlinck W van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta Ti bladder cancer: a meta-analysis of published results of randomized clinical trials. J 171(6 Pt 1), 2186–2190 (2004). Proves the value of primary chemotherapy.
   Google Scholar
• Shelley MD, Kynaston H, Court J et al. A systematic review of intravesical bacillus Calmette—Guerin plus transurethral resection vs. transurethral resection alone in Ta and Ti bladder cancer. BJU88(3),209–216 (2001).
   PubMed Web of Science ®Google Scholar
• Krege S, Giani G, Meyer R et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette—Guerin. j Lira 156,962–966 (1996).
   Google Scholar
• Vegt PD, Witjes JA, Witjes WPJ et al. A randomized study of intravesical mitomycin C, bacille Calmette—Guerin tice and bacille Calmette—Guerin RIVM treatment in pTa—pT1 papillary carcinoma and carcinoma in situ of the bladder. Uroll 153,929–933 (1995).
   PubMed Web of Science ®Google Scholar
• Rintala E, Jauhianien K, Alfthan O et al. Intravesical chemotherapy (MMC) versus immunotherapy (BCG) in superficial bladder cancer. Eur. Uml. 20,19 (1991).
   PubMed Web of Science ®Google Scholar
• Malmström PU, Wijkström H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette—Guerin in patients with superficial bladder carcinoma. Swedish—Norwegian Bladder Cancer Study Group. Br. Lira 161,1124–1127 (1999).
   Google Scholar
• Witjes JA, v d Meijden AP, Sylvester LC, Debruyne FM, van Aubel A, Witjes WE Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette—Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Co-operative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology52,403–410 (1998).
   Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette—Guerin immunotherapy for recurrent TA, Ti and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. UroL 163, 1124–1129 (2000).
   Google Scholar
• Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical bacillus Calmette—Guerin versus mitomycin C for Ta and Ti bladder cancer. Cochrane Database Syst. Rev 3, CD003231 (2003).
   Google Scholar
• ••Summary of trials comparing chemotherapyand bacillus Calmette—Guerin (BCG).
   Google Scholar
• Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette—Guerin versus mitomycin C for superficial bladdercancer: a formal meta-analysis of comparative studies on recurrence andtoxicity. j Urol. 169(1), 90–95 (2003).
   PubMed Web of Science ®Google Scholar
• Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: meta-analytic re-evaluation. Am. .1. Clin. OncoL 26(4), 402–407 (2003).
   Google Scholar
• •• Indicates methodological problems in earlier meta-analyses.
   Google Scholar
• Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette—Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. 1 Uml. 168, 1964–1970 (2002).
   Google Scholar
• ••Proves the value of maintenance BCG.
   Google Scholar
• Nadler RB, Catalona WJ, Hudson MA, Ratliff TL. Durability of the tumor-free response for intravesical bacillus Calmette—Guerin therapy. .1. UroL 152, 367–373 (1994).
   Google Scholar
• Badalament RA, Herr HVV, Wong GY et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette—Guerin therapy of superficial bladder cancer. Clin. OncoL 5441–5449 (1987).
   Google Scholar
• Hudson MA, Ratliff TL, Gillen DP, Haaff EO, Dresner SM, Catalona WJ. Single course versus maintenance bacillus Calmette—Guerin therapy for superficial bladder tumors: a prospective, randomized trial. UroL 138, 295–298 (1987).
   Google Scholar
• Palou J, Laguna P, Millan-Rodriguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodriguez J. Control group and maintenance treatment with bacillus Calmette—Guerin for carcinoma in situ and/or high grade bladder tumors. .1. UroL 165, 1488–1491 (2001).
   Google Scholar
• Lamm DL, Riggs DR, Traynelis CL et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J, UroL 153, 1444–1450 (1995).
   PubMed Web of Science ®Google Scholar
• Kaasinen E, Wijkström H, Malmström PU et al. Alternating mitomycin C and BCG instillations versus BCG alone in the treatment of carcinoma in situ of the urinary bladder. A Nordic study. Eur. Urn]. 43(6), 637–645 (2003).
   Google Scholar
• O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-a2b plus low dose bacillus Calmette—Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette—Guerin alone previously failed. 1 UroL 166, 1300–1304 (2001).
   Google Scholar
• Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of non-muscle invasive bladder cancer (stages Ta, Ti and TIS). The American Urological Association.' UroL 162, 1697–1701 (1999).
   Google Scholar
• Oosterlinck W, Lobel B, Malmström PU, Stöckle M, Sternberg U. EAU guidelines on urinary bladder cancer 2000. Eur. UroL 41(2), 105–112 (2002).
   Google Scholar
• Schmitz-Drager BJ, Goebell PJ, Ebert T, Fradet Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur. UroL 38(6), 691–699 (2000).
   Google Scholar
• Masters JR, Vani UD, Grigor KM et al. for the MRC Superficial Bladder Cancer Group Mitomycin-C Trial Collaborators. Can p53 staining be used to identify patients with aggressive superficial bladder cancer?' PathoL 200(i), 74–81 (2003).
   Google Scholar
• •Important paper regarding methodological assessment of a predictive factor.
   Google Scholar
• Au JL, Kalns K, Gan Y et al. Pharmacologic effects of paclitaxel in human bladder tumors. Cancer Chernother. Pharrnacol. 41, 69–74 (1997).
   PubMedGoogle Scholar
• Nativ O, Aronson M, Medalia O et al. Antineoplastic activity of paclitaxel on experimental superficial bladder cancer; in vivo and in vitro studies. Int. .1. Cancer 70, 297–301 (1997).
   Google Scholar
• Song D, Wientejes MG, Au JL. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chernother. PharmacoL 40, 285–292 (1997).
   Google Scholar
• Dalbagni G, Russo P, Sheinfeld J et al. Phase I trial of intravesical gemcitabine in bacillus Calmette—Guerin-refractory transitional-cell carcinoma of the bladder. .1. Clin. OncoL 20(15), 3193–3198 (2002).
   Google Scholar
• Nygren P, Csoka K, Larsson R, Busch C, Wester K, Malmström PU. Activity of standard and investigational cytotoxic drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomas. j UroL 162, 2200–2204 (1999).
   Google Scholar
• Maier U, Baumgartner G. Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial." Urol. 141, 529–530 (1989).
   Google Scholar
• Brausi M, Campo B, Pizzocaro G et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology51, 506–509 (1998).
   PubMed Web of Science ®Google Scholar
• Rigatti P, Lev A, Colombo R. Combined intravesical chemotherapy with mitomycin-C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study. Eur. Uml. 20, 204–210 (1991).
   Google Scholar
• Colombo R, Da Pozzo LF, Lev A et al. Neoadjuvant combined microwave induced hyperthermia and topical chemotherapy alone for superficial bladder cancer. .1. UroL 155, 1227–1232 (1996).
   Google Scholar
• Pagliaro LC, Keyhani A, Williams D et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a Phase I study of p53 gene therapy. Cum OncoL 21(12), 2247–2253 (2003).
   Google Scholar
• Loskog A, Bjorkland A, Brown MP, Korsgren O, Malmström PU, Tötterman TH. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. .1. UroL 166, 1093–1097 (2001).
   Google Scholar
• Akaza H, Kurth KH, Williams R, Hinotusu S. Intravesical chemotherapy and immunotherapy for superficial tumors: Basic mechanism of action and future direction. Urol. Orrcol. 4, 121–129 (1998).
   PubMedGoogle Scholar
• Nilsson S, Ragnhammar P, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta OncoL 40, 371–390 (2001).
   Google Scholar
• Bird V, Soloway M, Malmström PU. Intravesical chemotherapy in the treatment of superficial bladder cancer. In: Bladder Cancer: Current Diagnosis and Treatment. Droller M (Ed.), Humana press Inc., NJ, USA, 8, 183–223 (2001).
   Google Scholar